Floatz logo

cm-101

Nonalcoholic Steatohepatitis (NASH)

ChemomAb Ltd.Phase 1Dormant
CC
47/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
32/ 100
Competitive Position
95/ 100

Competitive context

131 Active assets in the Nonalcoholic Steatohepatitis (NASH) cohort.

Asset / SponsorPhaseRating
Resmetirom
City University of New York
Phase 4BBB
Pentoxifylline
Al-Azhar University
Phase 4BBB
Pioglitazone
Badr University
Phase 4BBB
Semaglutide
Cascade Pharmaceuticals, Inc
Phase 4BBB
Firsocostat
Gilead Sciences
Phase 2BBB

View all 50 →

Same molecule, other indications

cm-101 is also rated in:

metabolic dysfunction-associated steatohepatitisDormant
BB
Indicative ·
64 / 100
View asset →
primary sclerosing cholangitisDormant
B
Indicative ·
61 / 100
View asset →
systemic sclerosisDormant
CC
Indicative ·
46 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →